Trial · NCT05460325
Results by group67
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 67
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) | Lanadelumab 300 mg | TEAEs: Non-Angioedema Attack | 15 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) | Lanadelumab 300 mg | TEAEs: Angioedema Attack | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) | Lanadelumab 300 mg | SAEs: Non-Angioedema Attack | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) | Lanadelumab 300 mg | SAEs: Angioedema Attack | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) | Lanadelumab 300 mg | AESIs: Non-Angioedema Attack | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) | Lanadelumab 300 mg | AESIs: Angioedema Attack | 0 | Participants | |
| Number of Participants With Clinically Meaningful Changes in Clinical Laboratory Parameters | Lanadelumab 300 mg | 0 | Participants | ||
| Number of Participants With Clinically Meaningful Changes in Vital Sign Abnormalities | Lanadelumab 300 mg | 0 | Participants | ||
| Number of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG) | Lanadelumab 300 mg | 0 | Participants | ||
| Number of Participants With Clinically Significant Physical Examination Abnormalities on Day 182 | Lanadelumab 300 mg | Dermatologic System | 2 | Participants | |
| Number of Participants With Clinically Significant Physical Examination Abnormalities on Day 182 | Lanadelumab 300 mg | Extremities | 1 | Participants | |
| Plasma Concentrations of Lanadelumab | Lanadelumab 300 mg | Day 0 | 7.64 | Standard Deviation 24.096 | nanograms per milliliter (ng/mL) |
| Plasma Concentrations of Lanadelumab | Lanadelumab 300 mg | Day 14: Pre-dose | 12336.47 | Standard Deviation 4531.386 | nanograms per milliliter (ng/mL) |
| Plasma Concentrations of Lanadelumab | Lanadelumab 300 mg | Day 56: Pre-dose | 24857.89 | Standard Deviation 6950.725 | nanograms per milliliter (ng/mL) |
| Plasma Concentrations of Lanadelumab | Lanadelumab 300 mg | Day 98: Pre-dose | 24170.00 | Standard Deviation 7260.426 | nanograms per milliliter (ng/mL) |
| Plasma Concentrations of Lanadelumab | Lanadelumab 300 mg | Day 140: Pre-dose | 23821.05 | Standard Deviation 8808.870 | nanograms per milliliter (ng/mL) |
| Plasma Concentrations of Lanadelumab | Lanadelumab 300 mg | Day 182: Pre-dose | 24610.00 | Standard Deviation 6599.673 | nanograms per milliliter (ng/mL) |
| Plasma Concentrations of Lanadelumab | Lanadelumab 300 mg | Day 210 | 12048.00 | Standard Deviation 3268.807 | nanograms per milliliter (ng/mL) |
| Plasma Kallikrein (pKal) Activity | Lanadelumab 300 mg | Day 0 | 10256.419 | Standard Deviation 3311.3810 | ng/mL |
| Plasma Kallikrein (pKal) Activity | Lanadelumab 300 mg | Day 14: Pre-dose | 4904.964 | Standard Deviation 1350.4121 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05460325/results